Myeloma Registry Platform (MYRIAM)
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsoriOMEDICO AG
About this trial
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.
Eligibility criteria
Qualifiers
MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment)
Age ≥ 18 years
Written informed consent
Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment
Disqualifiers
No systemic therapy for myeloma
Patients already enrolled in studies that prohibit any participation in other studies
Trial design
Treatments tested in this trial
- Routine care as per site standard.
Treatment groups
No treatment groups listed
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Multiple sites all over germanyRecruiting Multiple Sites
Germany
GermanySponsors and collaborators
iOMEDICO AG
Lead sponsor
Deutsche Studiengruppe Multiples Myelom (DSMM)
Collaborator
Source ClinicalTrials.gov